• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    MIRA Pharmaceuticals, Inc. - Common Stock (NQ: MIRA )

    1.060 +0.060 (+6.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 390,201
    Open 1.020
    Bid (Size) 1.080 (7)
    Ask (Size) 1.090 (63)
    Prev. Close 1.000
    Today's Range 1.000 - 1.090
    52wk Range 0.5100 - 5.010
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
    Via ACCESSWIRE
    EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
    MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in preclinical studies. 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -10.92%
    -10.92%
    1 Month
    -19.70%
    -19.70%
    3 Month
    N/A
    N/A
    6 Month
    +49.27%
    +49.27%
    1 Year
    +0.95%
    +0.95%

    More News

    Read More
    MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
    Via ACCESSWIRE
    EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain
    Via Benzinga
    MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
    Via ACCESSWIRE
    MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
    Via Benzinga
    Peering Into Mira Pharmaceuticals's Recent Short Interest
    Via Benzinga
    MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
    Via ACCESSWIRE
    Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
    Via News Direct
    Topics Cannabis
    Exposures Cannabis
    Why Mira Shares Are Trading Higher Today
    Via Benzinga
    MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
    Via ACCESSWIRE
    MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
    Via News Direct
    MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
    Via ACCESSWIRE
    MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
    Via ACCESSWIRE
    The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
    Via News Direct
    MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
    Via Benzinga
    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday
    Via Benzinga
    MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
    Via ACCESSWIRE
    MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024
    Via InvestorPlace
    MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
    Via ACCESSWIRE
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.